TDC
NNVC icon

Thompson Davis & Co’s NanoViricides NNVC Stock Holding History

Thompson Davis & Co’s Portfolio NNVC Stock Details NNVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-700
Closed -$22K – 1148
2016
Q2 		$22K Buy
+700
New +$25.5K 0.04% 436

Other funds holding NNVC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Bridgeway Capital Management
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Raymond James & Associates
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
PTB
Pioneer Trust Bank Salem, Oregon $441M AUM 21.13% 1-Year Est. Return

Thompson Davis & Co's NNVC Position: Q3 2016 in Review

Thompson Davis & Co sold out of NanoViricides (NNVC) in Q3 2016, closing a stake of 700 shares — an estimated $22K sold.

Thompson Davis & Co first reported a position in NNVC in Q2 2016 and held it in 1 quarter. The position peaked at $22K in Q2 2016. 41 funds tracked by Wall St. Rank hold NNVC as of Q3 2016.

  • Thompson Davis & Co reported no remaining NanoViricides position as of Q3 2016 after selling out during the quarter.
  • Thompson Davis & Co sold 700 NanoViricides shares in Q3 2016, an estimated $22K.
  • Thompson Davis & Co first reported a position in NanoViricides in Q2 2016 and held it in 1 quarter.
  • Thompson Davis & Co's NanoViricides position peaked at $22K in Q2 2016.
  • 41 funds tracked by Wall St. Rank held NanoViricides as of Q3 2016.

Based on Thompson Davis & Co's 13F filing for Q3 2016, filed 8 Nov 2016.